Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Active:	Yes
Cancer Type:	Head and Neck Cancer Unknown Primary	NCT ID:	NCT06082167
Trial Phases:	Phase II Phase III	Protocol IDs:	XL092-305 (primary) NCI-2024-03938 EU CTR: 2023-506308-24-00
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Exelixis Inc
NCI Full Details:	http://clinicaltrials.gov/show/NCT06082167

Summary

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of
zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in
combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic
head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have
not received prior systemic therapy for recurrent or metastatic disease.

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology
3320 Old Jefferson Road
Building 800
Athens, GA 30607
www.universitycancer.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.